Compare Procter & Gamble Co (PG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Sana Biotechnology Inc — how do they compare? Procter & Gamble Co trades at $143.06 (market cap $338.13B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Procter & Gamble Co is far larger — about 328.3× Sana Biotechnology Inc's market cap, and Procter & Gamble Co pays a 2.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PG | SANA | |
|---|---|---|
Market Cap | $338.13B | $1.03B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $5.92 |
52-Week Low | $138.10 | $2.68 |
Enterprise Value | $363.97B | $946.04M |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters and maintains robust profitability with a net margin of 18.44% and ROE of 30.13%. Recent news highlights its dividend reliability and supply chain enhancements, while analyst consensus leans bullish with a $162.50 price target.
PG offers steady growth and income appeal with a 69-year dividend growth streak, but premium valuation and soft demand outlook pose near-term risks. Upside hinges on execution amid economic pressures, with support at $143 and resistance at $146.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
